CRIS Current Research Information System

RINALDI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.581
NA - Nord America 1.407
AS - Asia 687
AF - Africa 90
OC - Oceania 14
SA - Sud America 9
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.789
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.393
IT - Italia 778
SG - Singapore 310
CN - Cina 244
SE - Svezia 175
DE - Germania 151
GB - Regno Unito 102
IN - India 66
RU - Federazione Russa 65
IE - Irlanda 64
FI - Finlandia 50
CI - Costa d'Avorio 44
NL - Olanda 39
CH - Svizzera 32
AT - Austria 25
FR - Francia 24
BG - Bulgaria 23
TG - Togo 23
ID - Indonesia 18
JO - Giordania 17
NG - Nigeria 17
AU - Australia 13
BE - Belgio 13
ES - Italia 12
HK - Hong Kong 12
CA - Canada 10
JP - Giappone 7
BR - Brasile 6
UA - Ucraina 6
HR - Croazia 5
IR - Iran 5
ZA - Sudafrica 5
HN - Honduras 3
LT - Lituania 3
PE - Perù 3
TR - Turchia 3
DK - Danimarca 2
EE - Estonia 2
GR - Grecia 2
PL - Polonia 2
SA - Arabia Saudita 2
VN - Vietnam 2
AL - Albania 1
EU - Europa 1
KG - Kirghizistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
MX - Messico 1
NZ - Nuova Zelanda 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 3.789
Salva come PNG Salva come JPEG
Città #
Singapore 256
Chandler 200
Bologna 161
Santa Clara 160
Ashburn 136
Milan 102
Southend 65
Dublin 63
Boardman 62
Fairfield 58
Princeton 46
Abidjan 44
Rome 44
New York 36
Helsinki 35
Wilmington 28
Turin 26
Lomé 23
Florence 22
Sofia 22
Woodbridge 22
Beijing 21
Bern 21
Seattle 21
Berlin 18
Houston 18
Jakarta 18
Abeokuta 17
Amman 17
Nuremberg 17
Falkenstein 16
Lappeenranta 15
Vienna 15
Genoa 14
Bremen 13
Guangzhou 13
Amsterdam 12
Boydton 12
Brussels 12
Des Moines 12
Reggio Emilia 12
Shanghai 12
Washington 12
Ann Arbor 11
Budrio 11
Hong Kong 11
Tappahannock 11
Adelaide 10
Cambridge 10
Nanjing 10
Redmond 10
San Diego 10
Verona 10
London 9
Council Bluffs 8
Los Angeles 8
Toronto 8
Hyderabad 7
Padova 7
Yubileyny 7
Casalecchio di Reno 6
Changsha 6
Jinan 6
Parma 6
Sassari 6
Shenzhen 6
Cesena 5
Chicago 5
Chongqing 5
Forlì 5
Marratxí 5
Modena 5
Springfield 5
Venezia 5
Westminster 5
Xi'an 5
Épalinges 5
Barcelona 4
Bhubaneswar 4
Bühl 4
Cincinnati 4
Deiva Marina 4
Falls Church 4
Ferrara 4
Johannesburg 4
Lenola 4
Lunano 4
Mountain View 4
Nanchang 4
Naples 4
Noventa di Piave 4
Paris 4
Pune 4
Redwood City 4
Sala Bolognese 4
Shenyang 4
Tianjin 4
Venice 4
Brescia 3
Chengdu 3
Totale 2.288
Salva come PNG Salva come JPEG
Nome #
Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study 169
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 147
Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study 141
Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study 134
Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals 128
Relationship between immune response to SARS-CoV2 vaccines and development of breakthrough infection in solid organ transplant recipients: the CONTRAST cohort 126
Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC–MS/MS 120
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 116
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia 115
Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study 111
Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study 105
Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction 104
Risk factors for candidemia in hospitalized patients with liver cirrhosis: a multicenter case-control-control study 100
Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections 94
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 94
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF) 93
Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis 88
The impact of carbapenemase-producing Enterobacteriaceae colonization on infection risk after liver transplantation: a prospective observational cohort study 83
Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study 83
Development of a Risk Prediction Model for Carbapenem-resistant Enterobacteriaceae Infection after Liver Transplantation: A Multinational Cohort Study 82
Evaluation of the Kinetics of Antibody Response to COVID-19 Vaccine in Solid Organ Transplant Recipients: The Prospective Multicenter ORCHESTRA Cohort 78
Predictive model for bacterial co-infection in patients hospitalized for COVID-19: a multicenter observational cohort study 77
Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring 76
Using machine learning to predict antibody response to SARS-CoV-2 vaccination in solid organ transplant recipients: the multicentre ORCHESTRA cohort 75
Gut microbiome dynamics and Enterobacterales infection in liver transplant recipients: A prospective observational study 72
Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept 65
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP 57
Suboptimal drug exposure leads selection of different subpopulations of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae in a critically ill patient 57
Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime/avibactam treatment 55
Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?" 54
Impact of a multidisciplinary management team on clinical outcome in ICU patients affected by Gram-negative bloodstream infections: a pre-post quasi-experimental study 49
LA CONTAMINAZIONE DEL LIQUIDO DI PERFUSIONE DELL’ORGANO NEL TRAPIANTO DI FEGATO:INCIDENZA, PROFILO MICROBIOLOGICO ED IMPATTO CLINICO. 49
Risk factors associated with bacteremia in COVID-19 patients admitted to intensive care unit: a retrospective multicenter cohort study 48
A retrospective multicentre study on dalbavancin effectiveness and cost-evaluation in sternotomic wound infection treatment: DALBA SWIT Study 48
An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients 48
Validation of the INCREMENT-SOT-CPE score in a large cohort of liver transplant recipients with carbapenem-resistant Enterobacterales infection 47
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in the treatment of critically ill patients with documented KPC-producing Klebsiella pneumoniae ventilator-associated pneumonia 45
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia 42
Successful and Safe Real-Time TDM-Guided Treatment of Invasive Pulmonary and Cerebral Aspergillosis Using Low-Dose Isavuconazole in a Patient with Primary Biliary Cirrhosis: Grand Round/A Case Study 42
Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non-renal solid organ transplant recipients? 41
Use of colistin in adult patients: A cross-sectional study 40
Prediction models for carbapenem-resistant Enterobacterales carriage at liver transplantation: A multicenter retrospective study 39
Survey on the approach to antibiotic prophylaxis in liver and kidney transplant recipients colonized with “difficult to treat” Gram‐negative bacteria 39
Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections among Critically Ill Patients 39
Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF) 38
Antimicrobial Resistance in Organ Transplant Recipients 37
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration 37
The impact of preservation fluid culture on graft site arteritis: a systematic review and metanalysis 30
Impact of a multidisciplinary management team on clinical outcome in ICU patients affected by Gram-negative bloodstream infections: a pre-post quasi-experimental study 30
Impact of Continuous Infusion Meropenem PK/PD Target Attainment on C-Reactive Protein Dynamics in Critically Ill Patients With Documented Gram-Negative Hospital-Acquired or Ventilator-Associated Pneumonia 30
Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study 28
Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing Enterobacterales Bloodstream Infections and/or Ventilator-Associated Pneumonia? 28
Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections? 27
Tolerability of pulsed high-dose L-AmB as pre-emptive therapy in patients at high risk for intra-abdominal candidiasis: A phase 2 study (LAMBDA study) 26
Pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam in peritoneal fluid in an orthotopic liver transplant recipient affected by bacteraemic complicated intra-abdominal infection: due to OXA-181-producing Klebsiella pneumoniae 26
Is acidemia at birth a risk factor for functional gastrointestinal disorders? 25
Impact on clinical outcome of follow-up blood cultures and risk factors for persistent bacteraemia in patients with gram-negative bloodstream infections: a systematic review with meta-analysis 22
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections 22
Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in a case series of orthotopic liver transplant recipients 22
Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study 17
COVID-19 clinical phenotypes in vaccinated and nonvaccinated solid organ transplant recipients: a multicenter validation study 14
Invasive aspergillosis in liver transplant recipientsin the current era 13
Is CMV DNAemia an early marker of CMV colitis in patients with active ulcerative colitis? 13
Impact of attaining an aggressive PK/PD target with continuous infusion beta-lactams on the clinical efficacy of targeted therapy of early post-transplant Gram-negative infections in critically ill OLT recipients. An interim analysis of a 3-year prospective, observational, study 8
Usefulness of a TDM-Guided Approach for Optimizing Teicoplanin Exposure in the Treatment of Secondary Bloodstream Infections Caused by Glycopeptide-Susceptible Enterococcus faecium 5
In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies 4
Totale 4.017
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.874
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.874
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202037 0 0 0 0 0 0 0 11 10 5 2 9
2020/2021215 17 4 6 0 21 8 15 10 46 34 19 35
2021/2022543 19 18 15 49 32 25 18 63 29 85 109 81
2022/2023918 55 103 32 99 108 84 36 66 167 36 67 65
2023/2024754 72 62 54 71 73 101 42 37 42 69 69 62
2024/20251.490 80 218 214 184 275 130 262 127 0 0 0 0
Totale 4.017